Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Imatinib Mesylate in Patients With Refractory Metastatic and/or Unresectable Adenocarcinoma of the Stomach or Gastroesophageal Junction

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	Over 18	NCI	CCC-PHII-37 2004-01-09, NCI-5734, NCT00068380, 5734

Trial Description

Purpose:

Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

This phase II trial is studying how well imatinib mesylate works in treating patients with refractory metastatic and/or unresectable stomach or gastroesophageal junction cancer.

Eligibility:

Eligibility criteria include the following:

• At least 19 years old
• Measurable disease
• No brain metastases
• More than 4 weeks since surgery
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive imatinib mesylate by mouth twice a day for as long as benefit is shown. Patients will be evaluated periodically for 1 month.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

California Cancer Consortium

Heinz-Josef Lenz, MD, Principal investigator		Ph: 323-865-3955; 800-865-0102 Email: lenz_h@ccnt.usc.edu

Registry Information
Official Title		A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Trial Start Date		2004-03-31
Registered in ClinicalTrials.gov		NCT00068380
Date Submitted to PDQ		2003-07-18
Information Last Verified		2006-04-17
NCI Grant/Contract Number		CM17101, CA33572

Back to Top